Assessment of Suppression of Cutaneous Allergic Responses and Pruritis by Topical Minocycline

• Status: Recruiting
• Trial end date: 2023-09-25
• Target enrollment: 0
• Participant gender: All

Summary

Adults with known respiratory allergy/asthma with known skin test sensitization will undergo repeat skin prick testing at 4 areas of both arms (bilateral forearms, bilateral upper arms). Each site will be challenged with up to three known allergens, saline and histamine controls. Mean wheal diameter after 20 minutes challenge will be determined. This is followed by placement of minocycline cream (0%, 1%, 2%, 3%), placed in randomized fashion at each of 1 of 4 skin test sites. Measurement of subsequent wheal diameter will be done at 30 minutes, 60 minutes and 24 hours.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: State University of New York - Downstate Medical Center
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Adult ( ages 18-75) outpatients with diagnosis of allergic rhinoconjunctivitis and/or asthma who have previously undergone epicutaneous skin prick testing with detection of at least one allergen positive.

Exclusion Criteria:

• Subjects who are unable/unwilling to undergo cessation of oral antihistamines for five days prior to testing.

• Current use of oral steroids or other systemic immunosuppressants, including omalizumab (anti-IgE therapy) and anti-IL-5 therapy.

• Allergic asthmatics who have current uncontrolled asthma.